{"id":52779,"date":"2023-01-10T23:02:21","date_gmt":"2023-01-10T22:02:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/"},"modified":"2023-01-10T23:02:21","modified_gmt":"2023-01-10T22:02:21","slug":"geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/","title":{"rendered":"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million"},"content":{"rendered":"
\n

FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters\u2019 option to purchase additional shares of common stock for total gross proceeds of $227.8 million. All of the securities in the offering were sold by Geron.\n<\/p>\n

<\/a><\/p>\n

\nThe estimated net proceeds to Geron from this underwritten public offering, after deducting the underwriting discount and other estimated offering expenses, are approximately $213.3 million. Geron currently intends to use the net proceeds from this public offering, together with its existing cash, cash equivalents, restricted cash and current and noncurrent marketable securities, to fund preparatory activities for the potential U.S. commercial launch of imetelstat in lower risk MDS, and, if approved, to fund the potential U.S. commercial launch of imetelstat. Geron intends to use the remaining proceeds, if any, for working capital and general corporate purposes.\n<\/p>\n

\nThe public offering consisted of 68,007,741 shares of Geron\u2019s common stock at a price to the public of $2.45 per share, including 12,131,444 shares of common stock pursuant to the full exercise of the underwriters\u2019 option to purchase additional shares, and pre-funded warrants to purchase 25,000,000 shares of Geron\u2019s common stock at a price to the public of $2.449 per pre-funded warrant.\n<\/p>\n

\nGoldman Sachs & Co. LLC and Stifel acted as joint book-running managers for the offering. Wedbush PacGrow and Baird acted as co-lead managers for the offering. B. Riley Securities and Needham & Company acted as co-managers for the offering.\n<\/p>\n

\nAn automatically effective shelf registration statement on Form S-3 relating to the public offering of the shares of common stock and pre-funded warrants described above was filed with the Securities and Exchange Commission (SEC) on January 4, 2023. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC\u2019s web site at www.sec.gov<\/a>. When available, copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Goldman Sachs & Co. LLC, at Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by email at prospectus-ny@ny.email.gs.com<\/a>; and Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at 415-364-2720 or by email at syndprospectus@stifel.com<\/a>.\n<\/p>\n

\nThis press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.\n<\/p>\n

\nAbout Geron<\/b>\n<\/p>\n

\nGeron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases.\n<\/p>\n

\nUse of Forward-Looking Statements<\/b>\n<\/p>\n

\nInvestors are cautioned that statements in this press release regarding the anticipated gross and net proceeds from the offering and Geron\u2019s intended use of the net proceeds from this public offering constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: higher than estimated offering expenses; market and other conditions; and the impact of general economic, industry or political conditions in the United States or internationally and the current or evolving effects of macroeconomic conditions, such as the COVID-19 pandemic, civil or political unrest or military conflicts around the world, such as the military conflict between Ukraine and Russia, inflation, rising interest rates or prospects of a recession, on Geron\u2019s business operations and activities. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on other potential factors that could affect Geron\u2019s results and other risks and uncertainties can be found under the heading \u201cRisk Factors\u201d or other similar headings found in documents Geron files from time to time with the SEC, including Geron\u2019s current report on Form 8-K filed with the SEC on January 4, 2023 and the final prospectus supplement related to the offering related to the offering filed on January 6, 2023. Geron expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAron Feingold
\n
Investor and Media Relations
\n
investor@geron.com<\/a>
media@geron.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters\u2019 option to purchase additional shares of common stock for total gross proceeds of $227.8 million. All of the securities in … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52779","6":"format-standard","7":"category-industry"},"yoast_head":"\nGeron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters\u2019 option to purchase additional shares of common stock for total gross proceeds of $227.8 million. All of the securities in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-10T22:02:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230110005783\/en\/1626764\/21\/Geron_Full_Logo_RGB-01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million\",\"datePublished\":\"2023-01-10T22:02:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/\"},\"wordCount\":815,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005783\\\/en\\\/1626764\\\/21\\\/Geron_Full_Logo_RGB-01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/\",\"name\":\"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005783\\\/en\\\/1626764\\\/21\\\/Geron_Full_Logo_RGB-01.jpg\",\"datePublished\":\"2023-01-10T22:02:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005783\\\/en\\\/1626764\\\/21\\\/Geron_Full_Logo_RGB-01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005783\\\/en\\\/1626764\\\/21\\\/Geron_Full_Logo_RGB-01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/","og_locale":"en_US","og_type":"article","og_title":"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million - Pharma Trend","og_description":"FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters\u2019 option to purchase additional shares of common stock for total gross proceeds of $227.8 million. All of the securities in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-10T22:02:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230110005783\/en\/1626764\/21\/Geron_Full_Logo_RGB-01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million","datePublished":"2023-01-10T22:02:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/"},"wordCount":815,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230110005783\/en\/1626764\/21\/Geron_Full_Logo_RGB-01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/","url":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/","name":"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230110005783\/en\/1626764\/21\/Geron_Full_Logo_RGB-01.jpg","datePublished":"2023-01-10T22:02:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230110005783\/en\/1626764\/21\/Geron_Full_Logo_RGB-01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230110005783\/en\/1626764\/21\/Geron_Full_Logo_RGB-01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/geron-corporation-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-plus-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-total-gr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52779"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52779\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}